Innoviva

Q4 2025 -2.73%Q3 2025 +13.12%Q2 2025 +1.04%Q1 2025 -0.91%Q4 2024 -1.96%Q3 2024 +2.93%Q2 2024 +1.58%Q1 2024 -1.55%Q4 2023 -0.72%Q3 2023 +7.01%Q2 2023 -1.35%Q1 2023 +4.45%Q4 2022 -5.17%Q3 2022 +5.06%Q2 2022 -1.73%Q1 2022 +0.93%Q4 2021 +13.71%Q3 2021 +8.80%Q2 2021 +6.33%Q1 2021 +0.86%Q4 2020 +0.97%Q3 2020 +11.32%Q2 2020 +0.44%Q1 2020 +5.27%Q4 2019 +3.50%Q3 2019 +6.22%Q2 2019 -15.08%Q1 2019 +6.49%Q4 2018 -3.31%Q3 2018 +2.28%Q2 2018 -1.22%Q1 2018 -2.87%Q4 2017 +8.51%Q3 2017 -11.88%Q2 2017 +4.35%Q1 2017 -8.29%Q4 2016 +1.74%Q3 2016 -1.64%Q2 2016 +9.16%Q1 2016 -1.04%Q4 2015 +14.55%Q3 2015 +1.15%Q2 2015 -10.82%Q1 2015 -6.27%Q4 2014 +10.84%Q3 2014 -5.01%Q2 2014 +4.52%Q1 2014 -1.10%Q4 2013 -2.08%Q3 2013 +8.29%Q2 2013 -3.68%Q1 2013 +11.33%Q4 2012 -4.92%Q3 2012 -9.42%Q2 2012 -7.07%Q1 2011 -1.87%Q1 2012 +19.44%Q4 2011 +0.77%Q3 2011 +8.64%Q2 2011 +1.35%Q4 2010 -1.05%Q3 2010 +2.74%Q2 2010 +7.98%Q1 2010 -9.20%

Feb 03, 2021

•

Dec 31, 2020

Innoviva Q4 2020 Earnings Report

Reported financial results for the fourth quarter ended December 31, 2020

Key Takeaways

Innoviva reported strong Q4 2020 results with global net sales increases for RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, and TRELEGY® ELLIPTA® by 5%, 10%, and 42% respectively, compared to the same quarter of 2019. The company successfully deployed nearly $400 million of capital across promising assets.

RELVAR®/BREO® ELLIPTA® global net sales increased by 5% in Q4 2020 compared to Q4 2019.

ANORO® ELLIPTA® global net sales increased by 10% in Q4 2020 compared to Q4 2019.

TRELEGY® ELLIPTA® global net sales increased by 42% in Q4 2020 compared to Q4 2019.

Innoviva deployed nearly $400 million of capital across promising assets.